FDA Proposes Rule to Admit NAC as Supplement Ingredient

  • FDA proposes making NAC the first ingredient admitted through a new exception to the dietary supplement definition.
  • The agency will accept comments for 60 days and continue temporary enforcement discretion during rulemaking.

The U.S. Food and Drug Administration, the federal food and drug regulator, on Nov. 16 proposed a rule that would allow N-acetyl-L-cysteine to be lawfully marketed in dietary supplements. The FDA NAC proposed rule is scheduled for Federal Register publication on Nov. 17 and would remain open for public comment for 60 days.

If finalized, the rule would create 21 CFR 190.1 and list NAC as the first ingredient permitted through an exception to the dietary supplement definition’s drug preclusion provision. Manufacturers could market NAC products as supplements only when those products otherwise comply with the Federal Food, Drug, and Cosmetic Act, including requirements governing cGMP, adulteration, misbranding and product claims.

The agency concluded in 2022 that NAC was excluded because it had been approved as a drug before being marketed as a dietary supplement. It then adopted temporary enforcement discretion for certain compliant NAC products. FDA said that policy will continue while the rulemaking proceeds, and its current review identified no safety concerns with NAC use in or as a dietary supplement.

The Council for Responsible Nutrition welcomed the proposed pathway while saying the rule does not establish predictable criteria for other ingredients affected by drug preclusion. The association said it will evaluate the proposal and submit comments.

“We welcome FDA’s proposal to establish a regulatory pathway that would provide certainty for NAC.”

Steve Mister, president and CEO, Council for Responsible Nutrition

Sign up to the newsletter